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Summary:
Pneumocystis jirovecii causes pneumonia in immunosuppressed 
individuals. However, it has been reported the detection of 
low levels of Pneumocystis DNA in patients without signs and 
symptoms of pneumonia, which likely represents colonization. 
Several studies performed in animals models and in humans have 
demonstrated that Pneumocystis induces a local and a systemic 
response in the host. Since P. jirovecii colonization has been 
found in patients with chronic pulmonary diseases it has been 
suggested that P. jirovecii may play a role in the physiopathology 
and progression of those diseases. In this report we revise P. 
jirovecii colonization in different chronic pulmonary diseases such 
us, chronic obstructive pulmonary disease, interstitial lung diseases, 
cystic fibrosis and lung cancer.
KEY WORDS: Pneumocystis jirovecii, colonization, chronic pulmonary 
disease.
Résumé : COLONISATION PAR PNEUMOCYSTIS JIROVECII D’AFFECTIONS 
PULMONAIRES CHRONIQUES
Pneumocystis jirovecii est un agent de pneumonie chez les sujets 
immunodéprimés. Des faibles taux d’ADN de Pneumocystis peuvent 
cependant être détectés chez des patients sans pneumonie ; ils 
correspondraient à des situations de colonisation. Plusieurs études 
développées chez l’animal et chez l’homme ont montré que la 
colonisation par Pneumocystis peut induire chez l’hôte des réponses 
locale et systémique. Comme la colonisation peut être observée 
chez des patients atteints d’affections pulmonaires chroniques, 
il a été suggéré que P. jirovecii pourrait jouer un rôle dans la 
physiopathologie et l’aggravation de ces maladies. Dans cette revue, 
nous examinons la colonisation par P. jirovecii chez des patients 
atteints de maladies pulmonaires chroniques comme la broncho-
pneumopathie chronique obstructive, les fibroses pulmonaires 
interstitielles, la fibrose kystique et le cancer du poumon.
MOTS-CLÉS : Pneumocystis jirovecii, colonisation, broncho-pneumopathie 
chronique.
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INTRODUCTION
P neumocystis jirovecii (human-derived Pneu-mocystis) is an atypical opportunistic fungus with lung tropism and worldwide distribution 
that causes pneumonia in immunosuppressed indi-
viduals (Calderon et al., 2010). Although non-immu-
nosuppressed patients rarely develop Pneumocystis 
pneumonia (PcP) (Cano et al., 1993), it has been 
demonstrated that in respiratory samples of some 
subjects without signs and symptoms of pneumonia, 
can be detected low levels of Pneumocystis DNA that 
likely represent colonization (Wissmann et al., 2010). 
Other terms that have been used include “carriage”, 
“subclinical infection” and “asymptomatic infection” 
(Peterson et al., 2005). 
The first evidence reported of P. jirovecii colonization 
in patients with chronic bronchial diseases without 
immunosuppression was observed by using immu-
nofluorescence with monoclonal antibodies and stan-
dard stains. It was found that 10 % of patients was 
colonized (Calderón et al., 1996). Current detection of 
Pneumocystis colonization has been greatly facilitated 
by the development of sensitive molecular techniques, 
such as polymerase chain reaction (PCR) (Calderón et 
al., 2010). The rate of P. jirovecii colonization reported 
in chronic pulmonary diseases is diverse as a result of 
the used different sampling or detection procedures 
and the area where the study was performed (see 
Morris et al., 2008b for review), since P. jirovecii infec-
tion is apparently linked with environmental factors 
and probably there are low and high-risk geographical 
areas (Varela et al., 2004).
It has been reported that Pneumocystis induce in 
animals models alveolar macrophage activation, eleva-
tion of proinflammatory interleukins, changes in lung 
surfactant, type I pneumocyte degenerative changes, 
type II pneumocyte reparatory hypertrophy, alterations 
in alveolus-capillary permeability, diffuse alveolar 
damage and lung fibrosis (Prévost et al., 1998; Rice 
et al., 1993; Thomas et al., 2007). In addition, a study 
using a culture system revealed that Pneumocystis 
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major surface glycoprotein induces interleukin (IL)-8 
and monocyte chemoattractant protein-1 release from 
a human alveolar epithelial cell line (Benfield et al., 
1999). Besides, it has been recently demonstrated that 
colonized patients with chronic obstructive pulmonary 
disease (COPD) have higher systemic proinflammatory 
cytokine levels than do noncolonized patients (Cal-
derón et al., 2007). These data suggest that Pneumo-
cystis could play a role in the progression of chronic 
pulmonary diseases. 
On the other hand, colonized patients can act as a 
reservoir and source of infection for susceptible sub-
jects. In fact, the first molecular evidence that trans-
mission of P. jirovecii from colonized immunocom-
petent carriers to susceptible subjects may occur has 
been recently provided (Rivero et al., 2008). What’s is 
more, colonized individuals could represent a reservoir 
to P. jirovecii strains with dihydropteroate synthase 
(DHPS) gene mutations, potentially related with sulfa-
drugs resistance (Stein et al., 2004). In this sense, the 
finding of Pneumocystis DHPS gene mutations in two 
colonized patients with chronic bronchitis, who were 
not previously exposed to sulfa drugs (Calderón et al., 
2004), suggests either possible occurrence of sponta-
neous mutations or, most probably, transmission of 
mutant strains from HIV-infected patients (frequently 
submitted to sulfa prophylaxis). 
In this report we revise our current knowledge about 
P. jirovecii colonization in four major chronic lung 
diseases: COPD, interstitial lung diseases (ILDs), cystic 
fibrosis (CF) and lung cancer.
CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE
COPD is a major cause of illness, death, and the use of health care resources globally. The disease causes approximately 2.75 mil-
lion deaths annually, and the number is projected 
to increase. At present, it is the 4th most common 
cause of death among adults, and it is estimated to 
rank 3rd by 2020 (Chapman et al., 2006; Lopez et 
al., 2006). COPD is a slowly progressive condition 
characterized by airflow limitation that is not fully 
reversible. The airflow limitation is associated with a 
chronic inflammatory response in both airways and 
lung parenchyma (MacNee, 2005). Smoking is con-
sidered to be the major cause of COPD, but only a 
small portion of all smokers develops the disease. It 
has been hypothesized that cofactors, as P. jirovecii 
colonization, may play a role in COPD development 
(Morris et al., 2008a). Additionally, smoking would be 
a risk factor for P. jirovecii colonization in both HIV-
infected individuals (Morris et al., 2004a) and subjects 
with chronic pulmonary diseases (Vidal et al., 2006). 
Actually, cigarette smoking results in impaired muco-
ciliary clearance, which could facilitate P. jirovecii 
colonization. In short, Pneumocystis lower respiratory 
tract colonization, together with smoking, could be a 
cofactor that increase or maintain inflammatory res-
ponse, accelerating COPD progression. The rate of 
P. jirovecii colonization reported among patients with 
COPD is usually high. It shows however significant dif-
ferences (16 to 55 %) that suggest major geographical 
disparities in P. jirovecii epidemiology (Calderón et 
al., 2007; Nevez et al., 2006). Interestingly, among 
the COPD patients from a same geographical area P. 
jirovecii colonization is more prevalent in those with 
severe COPD (Morris et al., 2004b).
β-glucans are major structural components of cyst 
wall of Pneumocystis (Lebrón et al., 2003). β-glucans 
potently activate alveolar macrophages to release 
pro-inflammatory cytokines and chemokines through 
nuclear factor-κB (NF-κB) utilizing cellular receptors 
and signalling pathways distinct from bacterial lipo-
polysaccharide. β-glucans induce both cytokine gene-
ration and associated neutrophilic lung inflammation. 
In addition to Pneumocystis clearance, macrophages 
also strongly initiate inflammatory responses in the 
lung following interactions with β-glucan components 
of the organism, including secretion of tumor necrosis 
factor-α (TNF-α), IL-6, IL-8, macrophage inflammatory 
protein-2, eicosanoid metabolites, and reactive oxi-
dant species (Lebrón et al., 2003). These exuberant 
host inflammatory responses, though necessary for 
clearance of infection, further promote lung injury 
resulting in airspace inflammation and excessive mor-
bidity. The pulmonary inflammatory response against 
Pneumocystis resembles that associated with COPD 
and could therefore contribute to the pathogenesis of 
airway and parenchyma damage in subjects with this 
disease (Morris et al., 2008a).
An interesting study showed that Pneumocystis colo-
nization correlates with degree of airway obstruction 
independent of smoking history (Morris et al., 2004b). 
This study did not prove causality, but it strongly sug-
gests that Pneumocystis colonization affects COPD pro-
gression. In this sense, patients with COPD colonized 
by P. jirovecii were found to develop a higher systemic 
inflammatory response (increased levels of several cir-
culating cytokines and acute-phase reactants including 
IL-8, IL-6 and TNF-α) than do noncolonized patients 
(Calderón et al., 2007). In COPD patients, systemic 
inflammatory response has been linked to weight loss, 
muscle wasting and accelerate decrease in lung func-
tion (Gan et al., 2004). As a cause of systemic inflam-
matory response, Pneumocystis colonization could 
therefore play a role in the pathophysiology of COPD. 
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INTERSTITIAL LUNG DISEASES
ILDs are a heterogeneous group of disorders of the lower respiratory tract in which injury to the lung parenchyma leads to a cascade of inflamma-
tory and immune processes that cause lung fibrosis. 
The exact mechanism by which connective tissue 
proliferation occurs in some cases is unknown, 
although infectious agents have been implicated in 
the pathogenesis of ILDs (Egan et al., 1997, du Bois 
et al., 2003). In this way, it has been suggested that 
pulmonary inflammation, together with the adaptive 
immune response triggered by alveolar injury caused 
by Pneumocystis, could play a role in the pathoge-
nesis of ILDs and in the progression of the disease to 
fibrosis. The rate of P. jirovecii colonization in patients 
with ILDs ranged from 30 to 34 % (Vidal et al., 2006; 
Martín-Juan et al., 2008; Shimizu et al., 2009) and it is 
similar among different kind of ILDs (Martín-Juan et 
al., 2008) (Table I).
Interestingly, in a large study carried out in 240 
patients with ILDS (Martín-Juan et al., 2008), patients 
with ILDs who were carriers of P. jirovecii showed 
a significant higher peripheral blood total leukocyte 
and eosinophil levels compare to non-carriers. Also, 
the differential cell counts in the bronchoalveolar 
lavage fluid revealed a low CD4 ⁄ CD8 ratio in carrier 
patients, mainly because of an increased CD8+ T-cell 
count, although the differences did not reach statistical 
significance. This finding suggests that Pneumocystis 
colonization may be related to an exacerbation of 
these diseases. Further studies are needed in order to 
confirm the clinical significance of these findings.
CYSTIC FIBROSIS
CF is the most common serious hereditary disorder in the Caucasian populations. It is caused by several mutations in the CF trans-
membrane conductance regulator gene that map on 
the large arm of chromosome 7 (7q31.2) and encodes 
a chloride channel involved in electrolytic exchanges 
through the plasma membrane, leading to a defect in 
the mucociliary clearance and a thickness of the bron-
chial mucus (Rowe et al., 2005). Several organs are 
affected in this disease and pulmonary damage is the 
most serious clinical problem. An important factor that 
contributes to the development of pulmonary disease 
in patients with CF is persistent infection by oppor-
tunistic pathogens, mainly Pseudomonas aeruginosa, 
Staphylococcus aureus, Haemophilus influenza and 
Burkholderia cepacia (Rowe et al., 2005).
Recent researches indicate that a wide range of fungi 
can colonize the respiratory tract of patients with CF. 
Aspergillus fumigatus is the main fungus involved in 
fungal-related CF complication, however it is not the 
fungal infection itself which is mainly responsible 
for respiratory failure, instead the fungus grows in 
the upper respiratory way of CF patients, where it 
provokes repeated immune stimulation, such mecha-
nism leads to Allergic bronchopulmonary aspergillosis 
(ABPA), a chronic hypersensitivity condition that can 
lead to morbidity and ultimately to respiratory failure 
(Antunes et al., 2010).
Only a few published studies carried out in Europe 
have evaluated the prevalence of Pneumocystis coloni-
zation in patients with CF, reporting ranges from 1.3 % 
Interstitial lung diseases
Patients 
studied 
(n)
Patients with P. jirovecii 
colonization detected by 
molecular techniques (%)
Patients with P. jirovecii 
colonization detected by 
conventional and immuno-
fluorescence staining (%)
Idiopathic pulmonary fibrosis
Fibrosing lung disease associated with connective tissue disease
Sarcoidosis
Cryptogenic organizing pneumonia
Diffuse alveolar haemorrhage
69
38
35
31
20
22 (31.8 %)
13 (34.2 %)
10 (28.5 %)
 9 (29 %)
 8 (40 %)
4 (5.7 %)
2 (5.2 %)
2 (5.7 %)
1 (3.2 %)
2 (10 %)
Modified from Martín-Juan et al., 2008.
Table I. – Prevalence of Pneumocystis colonization in individuals with interstitial lung diseases from Andalucía (Spain).
Country
Number
of patients
Prevalence of Pneumocystis 
colonization (%)
Median age 
(years)
Chemoprophylaxis with 
co-trimoxazole (%) Authors, year
Germany
Spain
France
95
88
76
 7.4 %
21.6 %
 1.3 %
23.2
15.8
18.5
No
 2.3 %
39.5 %
Sing et al., 2001
Respaldiza et al., 2005
Gal et al., 2010
Table II. – Prevalence of Pneumocystis jirovecii colonization detected by using molecular methods among patients with cystic fibrosis.
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to 21.6 % (Table II) (Sing et al., 2001; Respaldiza et al., 
2005; Nevez et al., 2010). These differences in coloni-
zation rates could be related with differences in use of 
chemoprophylaxis with sulfa-drugs to prevent bacterial 
infections among the CF patients (Sing et al., 2001; 
Respaldiza et al., 2005; Gal et al., 2010). However, 
they could also be due to differences in population 
density, and in HIV infection or PcP incidence (Gal 
et al., 2010). On the other hand, several studies have 
shown seasonal changes of PcP incidence that seem to 
be associated with climate factors (Lubis et al., 2003; 
Varela et al., 2004; Sing et al., 2009). In this sense, 
the higher P. jirovecii colonization rates observed 
in patients with CF from Southern Europe than in 
patients from Northern Europe could be related with 
climate factors (Sing et al., 2001; Respaldiza et al., 
2005; Gal et al., 2010).
Pneumocystis colonization does not appear to be a 
risk factor for subsequent PcP in CF patients, pro-
bably because the immune status of these patients is 
usually enough to control the colonization to pneu-
monia shift (Sing et al., 2001; Respaldiza et al., 2005; 
Montes-Cano et al., 2007). However, even without 
deep immunosuppression, in chronic lung conditions 
Pneumocystis colonization could provoke mild or 
moderate respiratory illness, with the pathogen acting 
as a co-morbidity factor that may stimulate pulmonary 
inflammation and may play a pathogenic role (Cal-
derón et al., 2007; Morris et al., 2008b). Thus, it would 
be hypothesized that P. jirovecii colonization provokes 
airflow obstruction and inflammatory response in CF 
patients. However, to our knowledge, no evidence 
supporting this hypothesis was provided till now. In 
other words, it has not yet been established whether 
P. jirovecii colonization could have a role in worsening 
the natural course of CF. 
On the other hand, our knowledge of how P. jirovecii 
interact with pathogenic bacteria in the respiratory 
tract of patients with CF is completely unknown 
but this interaction could have some impact in the 
pathophysiology of CF. In this sense, a potential anta-
gonistic relation among P. jirovecii colonization and 
bacterial microbiota has been recently reported in the 
respiratory tract of patients with idiopathic interstitial 
pneumonia (Friaza et al., 2010).
LUNG CANCER
Tobacco smoking is the most important but not the only risk factor in lung carcinoma. The role of infectious agents in the develop-
ment of human tumours was not demonstrated until 
recently (Kuper et al., 2000). Actually, it is estimated 
that 15 % of all human cancers worldwide have an 
infectious origin (Pisani et al., 1997). Recently, it has 
been reported the first evidence of an association 
between small cell lung carcinoma and the presence 
of P. jirovecii colonization. In this study, in all the 
examined samples of small cell lung carcinoma P. 
jirovecii was detected (it was not found in metastases) 
(de la Horra et al., 2004). While the nature of this 
association is unclear, it nevertheless constitutes an 
important finding and open a new field for research 
since it is unknown either the P. jirovecii colonization 
is specifically facilitated by this tumour or induces the 
development of this type of neoplasm in combination 
with other factors. 
CONCLUSIONS
There is a high prevalence of P. jirovecii colo-nization in patients with chronic pulmonary diseases (Calderón, 2009). Data from different 
studies suggest a potential role of P. jirovecii in 
the pathophysiology of chronic pulmonary diseases 
through inducing inflammatory changes with chronic 
lung injury, but also interacting with other agents as 
tobacco or pathogenic bacteria (Calderón et al., 2007; 
Morris et al., 2008a; Christensen et al., 2008; Friaza et 
al., 2010). Understanding the role of P. jirovecii coloni-
zation in patients with chronic lung diseases may help 
us identify a novel, treatable pathogenic agent. 
On the other hand, P. jirovecii colonization in patients 
with chronic pulmonary diseases could represent a pro-
blem for public health since colonized patients could 
act as a major reservoir and source of infection for 
susceptible subjects (Calderón, 2009; Wissmann et al., 
2010). In the future, advances as real time PCR could 
enhanced the sensitivity of Pneumocystis DNA detection 
and to make research on Pneumocystis colonization 
epidemiology much easier. In this way, the role of non 
invasive marker serum as β-glucan levels in colonized 
patients should be explored (Krajicek et al., 2008). 
Further investigation is need to better define the epi-
demiology and the role of P. jirovecii colonization in 
the natural course of chronic pulmonary diseases and 
to determine the exact mechanism of its effects.
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